These results supported the further development and evaluation of SCB-1019 in combination with the PreF-Trimer antigens for hMPV and PIV3, which are also utilizing the Trimer-Tag platform.

Vaccines against both viruses, however, have been difficult to design. Now, Scripps Research scientists have analyzed the ...

These results supported the further development and evaluation of SCB-1019 in combination with the PreF-Trimer antigens for hMPV and PIV3, which are also utilizing the Trimer-Tag platform.

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health ...

Stable F proteins engineered for RSV and hMPV offer hope for effective vaccines to reduce severe infections in vulnerable ... Lee YZ, Han J, Zhang YN, et al. Rational design of uncleaved ...

These results supported the further development and evaluation of SCB-1019 in combination with the PreF-Trimer antigens for hMPV and PIV3, which are also utilizing the Trimer-Tag platform.

Furthermore, evaluation of SCB-1019 as part of a respiratory combination Trimer-Tagged PreF vaccine (RSV + hMPV ± PIV3) is also on track for Phase I clinical trial initiation in 2025.

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health ...

-- U.S. IND clearance and revaccination trial initiation supports the differentiated global opportunity for Clover's RSV PreF vaccine (SCB-1019) utilizing validated Trimer-Tag platform -- ...

-- Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage -- "We are pleased to announce the ...

These results supported the further development and evaluation of SCB-1019 in combination with the PreF-Trimer antigens for hMPV and PIV3, which are also utilizing the Trimer-Tag platform.